Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFM24 + SNK01 in Advanced EGFR-Expressing Cancers
NCT05099549Phase 2Terminated
- Sponsor
- NKGen Biotech
- Start
- Nov 2021
- Primary completion
- Sep 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
A Phase 2 trial of AFM24, troculeucel in colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), sponsored by NKGen Biotech. Started Nov 2021; status: terminated.
02
Drugs
AFM24troculeucel
03
Conditions
colorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05099549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05099549.